{"organizations": [], "uuid": "7b24f20d82887437b78e4592e211a8c0913be560", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abcam-says-entered-into-license-ag/brief-abcam-says-entered-into-license-agreement-with-roche-idUSL8N1PH1LX", "country": "US", "domain_rank": 408, "title": "BRIEF-Abcam Says Entered Into License Agreement With Roche​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.369, "site_type": "news", "published": "2018-01-22T16:45:00.000+02:00", "replies_count": 0, "uuid": "7b24f20d82887437b78e4592e211a8c0913be560"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abcam-says-entered-into-license-ag/brief-abcam-says-entered-into-license-agreement-with-roche-idUSL8N1PH1LX", "ord_in_thread": 0, "title": "BRIEF-Abcam Says Entered Into License Agreement With Roche​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - Abcam Plc:\n* ‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​\n* ‍WILL OBTAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO OF SPRING BIOSCIENCE CORPORATION IN RESEARCH USE ONLY (RUO) FIELD OF USE\n* ROCHE TO RETAIN ANTIBODY DEVELOPMENT CAPABILITIES, RIGHTS TO SPRING PORTFOLIO FOR INTERNAL RESEARCH, COMPANION DIAGNOSTIC, IVD USES​​\n* ALL PRODUCTS TO BE SOLD UNDER ABCAM BRAND, INCLUSIVE OF SP BRANDING, ARE EXPECTED TO BE AVAILABLE THROUGH ABCAM.COM FROM 21 FEBRUARY 2018​\n* GRANTED EXCLUSIVE RUO RIGHTS FOR FUTURE PRODUCTS DEVELOPED BY SPRING THAT ROCHE REQUESTS TO BE COMMERCIALISED IN RUO FIELD OF USE FOR INITIAL PERIOD OF 10 YEARS\n* ‍FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-22T16:45:00.000+02:00", "crawled": "2018-01-23T17:51:17.031+02:00", "highlightTitle": ""}